archived version — not current
This is a permanent, read-only archive of this profile's public content as it existed on 2026-09-27. It does not reflect the current, live profile. View the current profile.
Cagrilintide
Snapshot captured 2026-09-27 — Evidence added or removed
Overview
Cagrilintide is an amylin analog investigated for weight management, both alone and in combinations such as CagriSema. Evidence for the single agent must be separated from evidence for the combination.
Evidence quality
WPF’s existing atlas includes systematic reviews and network meta-analyses comparing cagrilintide, CagriSema, semaglutide, and other interventions. These syntheses pose different questions and may combine heterogeneous trials; a title or indirect comparison is not proof of relative superiority.
Safety concerns
No published source-linked citation or jurisdiction-specific regulatory record has been promoted into this Directory entry. Combined-treatment results cannot be attributed to cagrilintide alone, and follow-up duration and safety outcomes need separate appraisal.
Citations as of this version
- A Cross-Species Atlas of the Dorsal Vagal Complex Reveals Neural Mediators of Cagrilintide’s Effects on Energy Balance
- A combined cryo_EM structure of Cagrilintide-CTR-Gs complex
- 1969-LB: Effect of Combined Therapy with Once-Weekly Subcutaneous Cagrilintide 2.4 mg and Semaglutide 2.4 mg (CagriSema) on Energy Intake, Gastric Emptying, and Appetite in Adults with Overweight or Obesity
- A combined Cryo_EM structure of Cagrilintide-AMY1R-Gs complex
- Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials.
- Decision letter for "Efficacy and Safety of Cagrilintide and Cagrisema versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression"
- 26-A-15734-ACC CAGRILINTIDE-SEMAGLUTIDE (CAGRISEMA) VS SEMAGLUTIDE: SUPERIOR WEIGHT LOSS AND COMPARABLE SAFETY THROUGH SYNERGISTIC AMYLIN-GLP-1 CO-THERAPY: A META-ANALYSIS
- 1713-P: AT7687, a Novel GIP-Receptor Antagonist, Combined with Cagrilintide, Leads to Robust Weight Loss and Substantial Improvements in Insulin Sensitivity and Body Composition in Obese Insulin-Resistant Monkeys
- Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors.
- Review for "Efficacy and Safety of Cagrilintide and Cagrisema versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression"
- 26-A-9711-ACC CAGRISEMA VERSUS CAGRILINTIDE OR SEMAGLUTIDE MONOTHERAPY AS ANTI-OBESITY MEDICATIONS: A SYSTEMATIC REVIEW AND BAYESIAN NETWORK META-ANALYSIS WITH TRIAL SEQUENTIAL ANALYSIS
- Author response for "Efficacy and Safety of Cagrilintide and Cagrisema versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression"
- Decision letter for "Efficacy and Safety of Cagrilintide and Cagrisema versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression"
- 2458-P: Arcuate Hypothalamic Circuits Mediate Acute Cagrilintide-Induced Feeding in Mice
- Review for "Efficacy and Safety of Cagrilintide and Cagrisema versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression"
- Cagrilintide-semaglutide: a new option for patients with type 2 diabetes. (2026)
- Cellular loci for cagrilintide action identified. (2026)
- Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats. (2026)
- Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. (2026)
- Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. (2026)
- Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis. (2026)
- Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression. (2026)
- Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study. (2026)
- Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial. (2026)
- Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo. (2026)
- A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance. (2026)
- Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide. (2026)
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity. (2025)
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. (2025)
- Characterization of 0839 - A tool compound for pre-clinical mode-of-action studies of amylin analogues such as cagrilintide. (2025)
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. (2025)
- In adults with overweight or obesity, weekly subcutaneous cagrilintide-semaglutide increased weight loss at 68 wk. (2025)
- Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity. (2024)
- Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis. (2024)
- Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants. (2024)
- Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. (2023)
- Does receptor balance matter? - Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models. (2022)
- Cagrilintide plus semaglutide for obesity management. (2021)
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. (2021)
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. (2021)
- Development of Cagrilintide, a Long-Acting Amylin Analogue. (2021)
Regulatory status as of this version
- United States — FDA: not_approved
- European Union — EMA: not_approved
Content hash: 67e8c04731a5afa055204fbedb8ee18f7c9d862e32f80bcb161f36cc548843b7